The hottest news endoscopic surgery robot develope

2022-08-21
  • Detail

Newsletter | endoscopic surgery robot developer "Beijing Junrui" completed tens of millions of yuan of a-round financing, Shun Wei capital lead investment

newsletter | endoscopic surgery robot developer "Beijing Junrui" completed tens of millions of yuan of a-round financing, Shun Wei capital lead investment

2019- can be tested through tensile experiments 19:53 source://

original title: newsletter | endoscopic surgery robot developer "Beijing Junrui" completed tens of millions of yuan of a-round financing, Shun Wei capital led investment

the investment community (ID: PEDA, like the right hand to hold the joint of the swing rod ily2012) on February 28, the endoscopic surgery robot research and Development Company Beijing Junrui Technology Co., Ltd. announced that it had completed a round of financing of tens of millions of yuan. Shun Wei capital led the investment, huiding cornerstone followed the investment, and the old shareholder Tianfeng medical continued to support it. This round of financing will be mainly used to expand the R & D team, carry out clinical research, expand the scope of indications of surgical robots, improve the robot manufacturing system, and expand prototype production

established in 2014, Shurui is a high-tech enterprise committed to independent research and development, production and sales of minimally invasive surgical robot systems. Its headquarters are located in Beijing and has a research and development center in Shanghai. At present, its self-developed product - Zhurui EZ port ® The prototype of endoscopic surgery robot system has been developed and is expected to enter the clinical research program this year

endoscopic surgery robot is fully called "endoscopic surgical instrument control system", and the standard equipment is composed of console, surgical execution arm and imaging system. Compared with traditional surgery, the assisted participation of robots makes endoscopic surgery more intuitive and more accurate. As of 2018, the global endoscopic surgery robot market is still monopolized by Da Vinci series (Da Vinci) surgical robot system produced by American Intuitive Surgical company. However, Da Vinci surgical robot also has some disadvantages, such as high price, huge volume, and collision related optimization of strength and toughness of materials such as the United States, Japan and South Korea after the manipulator is easy to dry during surgery. In 2017, Da Vinci surgical robot implemented 20000 operations in China. Compared with the huge total number of operations in China, its penetration rate in the field of clinical surgery is still low, which leaves a certain development space for domestic endoscopic surgery robot R & D companies

compared with Leonardo da Vinci's surgical robot, the greatest features of surgical sharp robot are: first, it adopts a continuous snake shaped surgical execution arm with independent intellectual property rights, and adds a wrist structure at the end, making its surgical operation more flexible. Second, with the structural adaptability of the continuum mechanism, only a set of surgical sharpening robot system is needed to carry out a variety of surgical methods, such as single hole endoscopy, multi hole endoscopy and endoscopic therapy, which can provide a wider range of clinical applications. The robot systems of Da Vinci surgical robot for multi hole and single hole endoscopic surgery are different from each other, and hospitals need to purchase them separately

in terms of business model, cirrus plans to work from two aspects: Sales and leasing of complete machines, sales of robotic surgical consumables and training services. At present, Shu Rui has more than 100 Chinese and foreign patents. In the future, cirrus will continue its global layout of intellectual property rights and build its own complete intellectual property barriers in order to be more competitive in the international market

Copyright © 2011 JIN SHI